All In Biotech

Investigational drug · Phase 2

PEGPH20

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Adenocarcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

22

Any phase or sponsor naming "PEGPH20"

First trial start

2017

Jul 5, 2017

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PEGPH20", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pancreatic Adenocarcinoma

Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "PEGPH20" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 62 on PubMed

Also in development for Pancreatic Adenocarcinoma

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • GEMPhase 35 trials

    Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • zoldonrasibPhase 34 trials

    Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC

  • BL-8040Phase 32 trials

    BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma

  • CF102NamodenosonPhase 32 trials

    Can-Fite BioPharma · Pancreatic Adenocarcinoma, Pancreatic Cancer, Hepatocellular Carcinoma

  • AB928Etrumadenant, ETRUMAPhase 24 trials

    Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

  • ImzokitugBMS-986340Phase 22 trials

    Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.